Medtronic Misses Third-Quarter Revenue Views as Some Distributors Lower Inventory Levels

MT Newswires
19 Feb
medtronic -Shutterstock
Medtronic (MDT) reported fiscal third-quarter revenue below analyst projections as some distributors lowered their surgical inventory levels, weighing on the division's performance.

Revenue rose to $8.29 billion for the three months ended Jan. 24 from $8.09 billion the year earlier, but was shy of the $8.33 billion average analyst estimate in a FactSet poll. Adjusted earnings per share advanced to $1.39 from $1.30 year over year and topped the $1.36 consensus.

The medical device maker's shares fell 7.2% in Tuesday afternoon trade.

"A couple of our larger distributors" stepped down their surgical inventory levels below normal, Chief Executive Geoff Martha told analysts on a conference call, according to a FactSet transcript.

That change in US distributor buying patterns drove a negative impact of "a couple of hundred" basis points on the medical surgical division, Martha said on the call. The segment's sales dropped 1.9% to $2.07 billion.

"We do expect these dynamics to resolve as we enter (the first quarter), when these distributors reach their target inventory levels," he added.

In Medtronic's cardiovascular division, revenue climbed 3.7% to $3.04 billion on increased demand for its cardiac rhythm management solutions. Sales rose 4.4% to $2.46 billion in neuroscience.

Medtronic continues to expect fiscal 2025 year-over-year organic revenue growth of 4.75% to 5%. It now sees reported revenue rising 3.4% to 3.8%, lowering the top-end of its prior guidance from 3.9%. In fiscal 2024, the company reported revenue of $32.36 billion. The Street is modeling for $33.57 billion in the ongoing year.

Management reiterated a non-GAAP EPS guidance of $5.44 to $5.50, compared with $5.20 it reported last year. The market view is for adjusted EPS of $5.45 for fiscal 2025.

Medtronic expects to accelerate both top- and bottom-line growth in the fiscal fourth quarter, resulting in high-single-digit adjusted EPS growth in the second-half of the year, Gary Corona, Medtronic's interim chief financial officer, said in a statement.

















Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10